

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
		6102-000013/US/NP	10/585,609
		APPLICANT	
		Scheller, D., et al.	
		FILING DATE	GROUP
		July 10, 2006	1614

O I P E
NOV 3 0 2007
PATENT & TRADEMARK OFFICE

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 5

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
R1		4,542,135	Sep 17, 1985	Kobel et al.	514/250	Aug 03, 1982
R2		4,564,628	Jan 14, 1986	Horn	514/438	Aug 13, 1984
R3		4,722,933	Feb 02, 1988	Horn	514/438	Mar 17, 1986
R4		4,885,308	Dec 05, 1989	Horn	514/438	Jun 13, 1988
R5		5,071,875	Dec 10, 1991	Horn	514/613	Sep 25, 1989
R6		5,151,446	Sep 29, 1992	Horn et al.	514/617	Mar 28, 1991
R7		5,456,745	Oct 10, 1995	Roreger et al.	106/128	Aug 11, 1989
R8		5,496,843	Mar 05, 1996	Nagata et al.	514/411	Nov 14, 1994
R9		5,614,518	Mar 25, 1997	Leeson et al.	514/234.5	Nov 21, 1994
R10		5,807,570	Sep 15, 1998	Chen et al.	424/449	Sep 04, 1996
R11		5,807,855	Sep 15, 1998	Bogeso et al.	514/449	Oct 28, 1994
R12		5,891,461	Apr 06, 1999	Jona et al.	424/449	Sep 14, 1995
R13		6,010,877	Jan 04, 2000	Sathe et al.	435/69.1	Jan 10, 1997
R14		6,221,627	Apr 24, 2001	Sathe et al.	435/69.1	Feb 24, 1997
R15		2005/0182090	Aug 18, 2005	Mierau et al.	514/304	Jan 21, 2005
R16		2005/0197385	Sep 08, 2005	Scheller et al.	514/438	Feb 17, 2005

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/ Subclass	Translation Yes	Translation No
R301		CA 2 532 804	Feb 03, 2005	CA	A61K		
R302		CA 2 532 859	Feb 03, 2005	CA	A61K		
R303		CA 2 546 797	Jul 14, 2005	CA	A61K		
R304		CA 2 568 850	Feb 16, 2006	CA	CO7D		
R305		WO 93/00313	Jan 07, 1993	PCT	A61K		
R306		WO 94/26703	Nov 24, 1994	PCT	CO7C		
R307		WO 96/31210	Oct 10, 1996	PCT	A61K		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 2 of 5		ATTORNEY DOCKET NO.	SERIAL NO.
		6102-000013/US/NP	10/585,609
		APPLICANT	
		Scheller, D., et al.	
		FILING DATE	GROUP
		July 10, 2006	1614

FOREIGN PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Country	Class/ Subclass	Translation Yes No
R308		WO 97/29735	Aug 21, 1997	PCT	A61K	
R309		WO 99/49852	Oct 07, 1999	PCT	A61K	X
R310		WO 00/02053	Jun 13, 2000	PCT	GOIN	
R311		WO 00/03715	Jan 27, 2000	PCT	A61K	
R312		WO 00/35954	Jun 22, 2000	PCT	CO7K	
R313		WO 00/38669	Jul 06, 2000	PCT	A61K	
R314		WO 01/38321	May 31, 2001	PCT	CO7D	
R315		WO 01/39756	Jun 07, 2001	PCT	A61K	
R316		WO 02/15903	Feb 28, 2002	PCT	A61K	X
R317		WO 02/18382	Jul 03, 2002	PCT	C07D	
R318		WO 02/31499	Apr 18, 2002	PCT	GO1N	
R319		WO 02/38646	May 16, 2002	PCT	CO8G	X
R320		WO 02/89777	Nov 14, 2002	PCT	A61K	
R321		WO 02/89778	Nov 14, 2002	PCT	A61K	
R322		WO 03/007803	Jan 30, 2003	PCT	A61B	
R323		WO 03/012137	Feb 13, 2003	PCT	C12Q	X
R324		WO 03/029233	Apr 10, 2003	PCT	CO7D	
R325		WO 03/069332	Aug 21, 2003	PCT	A61K	
R326		WO 04/012721	Feb 12, 2004	PCT	A61K	X
R327		WO 04/012730	Feb 12, 2004	PCT	A61K	
R328		WO 04/012719	Feb 12, 2004	PCT	A61K	
R329		WO 06/050976	Mar 18, 2006	PCT	CO7D	X

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 3 of 5	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000013/US/NP	10/585,609
	APPLICANT	
	Scheller, D., et al.	
	FILING DATE	GROUP
	July 10, 2006	1614

OTHER DOCUMENTS (including Author, Title, Date, Pages, etc.)

Ref. Desig.	Examiner's Initials	
R501		Abbas (1999) Hum. Mol. Genet 8, 567
R502		Barzilai (2001) Cell Mol. Neurobiol. 21(3), 215-235
R503		Becker (2002) J. Neurol. 249(Suppl. 3) III/40-III/48
R504		Blanchet et al. (2004) Parkinsonism and Related Disorders 10, 297-304
R505		Borsini (1988) Eur. J. Pharmacol. 148, 301-307
R506		Burn (2000) The Pharmaceutical Journal 264, 476-479
R507		Camicioli (2002) R. Drugs Today (Barc) 38*10, 677-686
R508		Carp et al. (1982) Brain Research 242, 247-254
R509		Chan et al. (2004) Hospital Pharmacist 11, 18-22
R510		Chase et al. (1995) Clinical Neuropharmacology 18(1), S207-S215
R511		Dawson (2002) Nature Neuroscience Supplement, Vol 5, 1058-1061
R512		Den Daas (1990) Naunyn-Schmiedeberg's 342, 655-659
R513		Domino et al. (1983) J. Pharmacol. & Experimental Therapy Vol 264(1), 221-225
R514		Eberhardt (2003) Toxicology Letter 139(2), 135-151
R515		Fahn et al. (1987) Recent Developments in Parkinson's Disease Vol II, 153-163, 293-304
R516		Foley et al. (2004) J. Neural Transmission 111, 1375-1446
R517		Gerlach (2003) Neurotox. Res. 5(1), 43-51
R518		Gerlach et al. (2003) J. Neural Transm. 65(Suppl.), 167-183
R519		Guttman (2003) Canadian Med. Assoc. Journal 168(3), 293-301
R520		Hackling (2002) ChemBioChem 3, 947-961
R521		Hagan et al. (1997) TIPS Vol 18, 156-163
R522		Hauser et al. (2004) Neurol. Clin. 22, S149-S166
R523		Henderson (2003) J. Neurol. Neurosurg. Psychiatry 74, 956
R524		Hobson (2003) Can. J. Neurol. Sci. 30(Suppl 1) S2-S9
R525		Holcomb et al. (1982) Eur. J. Pharmacol. 82, 173-178
R526		Hornykiewicz (2002) Encyclopedia of Life Sciences Vol 13, 695-704

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 4 of 5	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000013/US/NP	10/585,609
	APPLICANT	
	Scheller, D., et al.	
	FILING DATE	GROUP
July 10, 2006	1614	

OTHER DOCUMENTS (including Author, Title, Date, Pages, etc.)

Ref. Desig.	Examiner's Initials	
R527		Hughes (1992) J. Neurol. Neurosurg. Psychiatry 55, 181-184
R528		Hutchinson et al. (1999) J. Neurol. Neurosurg. Psychiatry 67, 815-818
R529		Joyce (2001) Pharmacol. & Ther. 90, 231-259
R530		Kitada (1998) Nature 392, 605-608
R531		Korcyn et al. (2002) Drugs 62(5), 775-786
R532		Krygowska-Wajs (2000) Funct. Neurol. 15, 41
R533		Lee et al. (1982) Psychiatry Research 7, 111-119
R534		Lev (2003) Prog. Neuropsychopharm. Biol. Psychiatry 27(2), 245
R535		Levien (2005) Advances in Pharmacy 3(1), 62-92
R536		Li et al. (2000) Proceed Intl. Symp. Control Rel. Bioact. Mater, pp 952-953
R537		Li et al. (2001) Pharm. Research Vol. 18(11), 1509-1513
R538		Linazasoro (2004) Movement Disorders 19(7), 743-754
R539		Lucking (2000) N. Engl. J. Med. 342, 1560-1567
R540		Mackonochie (2003) March 31-April 3 Stuttgart, GER, Drug Discovery Tech. 2003 Seventh Annual Conference and Exhibition, Vol. 6, 420-422
R541		Matsumine (1997) Am. J. Hum. Genet. 60, 588
R542		Metman (2001) Clinical Neuropharmacology 24(3), 163-169
R543		Michel et al. (2002) Rev. Neurol. (Paris) 158 Spec No. 1, pp 7S24-7S32
R544		Modigh et al. (1984) Neurotransmitter & Receptor Mechanisms, 18-27
R545		Muramatsu et al. (2003) GLIA 42, 307-313
R546		Newman-Tancredi et al. (2002) J Pharmacology and Experimental Therapeutics 303(2), 805-814
R547		Nurse et al. (1984) Neurochemical Research 9(9), 1231-1238
R548		Nussbaum (2003) N. Engl. J. Medicine 348(14), 1356-1364
R549		Pankratz (2003) Am. J. Hum. Genet. 72, 1053-1057
R550		Park (2002) Drug Delivery Technology 2(5), July//August, http://www.drugdeliverytech.com/cgi-bin/issues.cgi?idIssue=6 and http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=60
R551		Pascual (1992) Annals of Neurology 32(5), 703-707

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 5 of 5	ATTORNEY DOCKET NO.	SERIAL No.
	6102-000013/US/NP	10/585,609
	APPLICANT	
	Scheller, D., et al.	
	FILING DATE	GROUP
	July 10, 2006	1614

OTHER DOCUMENTS (including Author, Title, Date, Pages, etc.)

Ref. Desig.	Examiner's Initials	
R552		Polymeropoulos (1997) Science 276, 2045-2047
R553		Prunier (2003) NeuroImage 19, 810-816
R554		Rammsayer (1997) Int. J. Neurosci. 91, 45
R555		Riederer (2000) J. Neurol. 247(4), IV/36-IV/37
R556		Scriabine (2003) CNS Drug Reviews 9(4), 389-395
R557		Sharma (2002) Neurol. Clin. N. Am. 20, 759-778
R558		Stern (2004) Annals of Neurology 56(2), 169-170
R559		Stiasny-Kolster et al. (2000) SLEEP, May 1, 23(3), 1-6
R560		Stichel and Scheller (2005) EFNS Conference, "Rotigotine Prevents Neurodegeneration in a Mouse Model of Parkinson's Disease"
R561		Stockmeier et al. (1997) Neuropsychopharmacology 16(2), 162-173
R562		Swart (1993) Toxicology Methods 3, 279, 289 last paragraph
R563		Swart (1994) J. Analytical Toxicology 18, 71-77
R564		Swart (1995) Pharmaceutical Sciences 1, 437-440
R565		Tassin (1998) Am. J. Hum. Genet. 63, 88-94
R566		Tuite (2003) Expert Opin. Investig. Drugs 12(8), 1335-1352
R567		Valente (2001) Am. J. Hum. Genet. 68, 895
R568		van der Geest et al. (1997) Pharm. Research Vol. 14, 1798-1803
R569		Van Dujin (2001) Am. J. Hum. Genet. 69, 629-634
R570		Vanacore (2002) Neurol. Sci. 23, S119
R571		Vila (2003) Nat. Rev. Neurosci 4(5), 365
R572		Waters (2005) Movement Disorder 20(1), S38-S44
R573		Wenning et al. (2004) Lancet Neurology 3, 93-103

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.